- Molecular diagnostics company Genetic Technologies (GTG) has appointed Simon Morriss as Chief Executive Officer as of February 2021
- Genetic Technologies also offer predictive testing and assessment tools to empower physicians to proactively manage patient health
- Along with a fixed salary of $350,000, Simon Morriss will be eligible to receive 60 million performance rights on commencement for nil consideration
- Simon Moriss has over 20 years of experience within the pharmaceutical and healthcare industries
- Additionally, the board has announced George Muchnicki, acting CEO since September 2019, will step into the role of Chief Medical Officer and Executive Director
- Genetic Technologies shares are up 6.67 percent, trading at 0.8 cents per share
